Membership

Our members receive our quarterly e-newsletter with members-only content including interviews with dermatologists, information on contests and draws, and are the first to hear about upcoming events.

Membership is free.

Learn More

List of Biologic & Biosimilar Drugs

Click on the names below to read more about each medication.

List of Biologics and Biosimilars (Psoriasis)

TNF Blockers
IL17 Blockers
IL12/23 Blockers
IL23 Blockers
IL36 Blocker (generalized pustular psoriasis flares)

List of Biologics and Biosimilars (Psoriatic Arthritis)

TNF Blockers
IL17 Blockers
IL12/23 Blockers
Abatacept

Etanercept (TNF Blocker)

How Does It Work?

Etanercept is a biologic that targets the overactive immune system in psoriasis. Etanercept works by supressing tumor necrosis factor-alpha (TNFa). Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Etanercept is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
50 mg twice weekly for 3 months, then 50 mg once weekly thereafter

For psoriatic arthritis: 
50 mg once weekly

What Are The Possible Side Effects?

The most common side effects of etanercept include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of etanercept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on etanercept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on etanercept.

Etanercept and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Etanercept should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Etanercept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with etanercept include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with etanercept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/ANAhttps://pdf.hres.ca/dpd_pm/00065129.PDFMarch 17, 2022
AlbertaBiologics and BiosimilarsEtanerceptEnbrel®Yes - pediatric patients weighing less than 63 kgNohttps://pdf.hres.ca/dpd_pm/00048003.PDFhttps://pdf.hres.ca/dpd_pm/00060454.PDFMarch 19, 2021
AlbertaBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/Ahttps://pdf.hres.ca/dpd_pm/00049267.PDFhttps://pdf.hres.ca/dpd_pm/00069556.PDFJan 18, 2023
British ColumbiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/A Yes – S/A
British ColumbiaBiologics and BiosimilarsEtanerceptEnbrel®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsEtanerceptErelzi™Yes - S/A Yes – S/A
ManitobaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis. Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis.
ManitobaBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS  Yes – EDS
New BrunswickBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/A Yes - S/A
New BrunswickBiologics and BiosimilarsEtanerceptEnbrel®No All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.
New BrunswickBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptEnbrel®Yes–S/A All new requests for coverage of etanercept received after March 1, 2018 will be approved for the biosimilar version only.Yes–S/A All new requests for coverage of etanercept received after March 1, 2018 will be approved for the biosimilar version only.
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
NIHBBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U (may vary by province)Yes – L/U (may vary by province/territory)
NIHBBiologics and BiosimilarsEtanerceptEnbrel®NoYes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars.
NIHBBiologics and BiosimilarsEtanerceptErelzi™Yes - L/UYes- L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U (may vary by province)Yes – L/U (may vary by province/territory)
Northwest TerritoriesBiologics and BiosimilarsEtanerceptEnbrel®NoYes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars.
Northwest TerritoriesBiologics and BiosimilarsEtanerceptErelzi™Yes - L/UYes- L/U
Nova ScotiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsEtanerceptEnbrel®No - barring exceptionNo - barring exception
Nova ScotiaBiologics and BiosimilarsEtanerceptErelzi™Yes - EDSYes – EDS
NunavutBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U (may vary by province)Yes – L/U (may vary by province/territory)
NunavutBiologics and BiosimilarsEtanerceptEnbrel®NoYes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars.
NunavutBiologics and BiosimilarsEtanerceptErelzi™Yes - L/UYes- L/U
OntarioBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U Yes – L/U
OntarioBiologics and BiosimilarsEtanerceptEnbrel®Yes – L/U No 
OntarioBiologics and BiosimilarsEtanerceptErelzi™Yes – L/U Yes – L/U
Prince Edward IslandBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsEtanerceptErelzi™Yes-S/AYes – S/A
QuebecBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. If treatment and reimbursement began before August 19 2020.Yes – S/A. If treatment and reimbursement began before August 19 2020.
QuebecBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A 
SaskatchewanBiologics and BiosimilarsEtanerceptBrenzys®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsEtanerceptEnbrel®No. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation No. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation 
SaskatchewanBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS Yes – EDS
YukonBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U (may vary by province)Yes – L/U (may vary by province/territory)
YukonBiologics and BiosimilarsEtanerceptEnbrel®NoYes - L/U Effective october 2, 2017, all nihb program clients who are etanercept-naïve and whose therapy is initiated on or after this date, an etanercept biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for enbrel before october 2, 2017 will continue to have this brand covered and will also be eligible for coverage of etanercept biosimilars.
YukonBiologics and BiosimilarsEtanerceptErelzi™Yes - L/UYes- L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Enbrel®: https://pdf.hres.ca/dpd_pm/00048003.PDF
Erelzi™: https://pdf.hres.ca/dpd_pm/00049267.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Etanercept (Enbrel®): https://www.amgen.ca/products/patient-assistance/
Etanercept biosimilar (Erelzi™): Call 1-844-27XPOSE (1-844-279-7673) for information

Brenzys
Harmony patient support program
Phone 1-866-556-5663
https://rheuminfo.com/docs/physician-tools/patient-support-programs/Brenzys_EN.pdf

↑ Back to list of biologics and biosimilars

Adalimumab (TNF Blocker)

How Does It Work?

Adalimumab is a biologic that targets the overactive immune system in psoriasis. Adalimumab works by supressing tumor necrosis factor (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Adalimumab is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
80 mg as an initial dose, then 40 mg every other week starting one week after initial dose

For psoriatic arthritis:
40 mg every other week

What Are The Possible Side Effects?

The most common side effects of adalimumab include temporary pain and redness around the injection site, headaches, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of adalimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on adalimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on adalimumab.

Adalimumab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Adalimumab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with adalimumab include abatacept (Orencia®), anakinra (Kineret®) and other TNF-blockers such as Enbrel®, Remicade®, Cimzia®, or Simponi®. Adalimumab can potentially affect the speed at which cyclosporine and warfarin are metabolized and their doses may need to be adjusted. For a complete list of medications that may interact with adalimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsAdalimumabAbrilada®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00068228.PDFNov 14, 2022
AlbertaBiologics and BiosimilarsAdalimumabAmgevita®NoNoNAhttps://pdf.hres.ca/dpd_pm/00067468.PDF9 September, 2022
AlbertaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00068763.PDFDec 14, 2022
AlbertaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00068848.PDFDecember 22, 2022
AlbertaBiologics and BiosimilarsAdalimumabHumira®No No https://pdf.hres.ca/dpd_pm/00052133.PDFhttps://pdf.hres.ca/dpd_pm/00068848.PDFDecember 22, 2022
AlbertaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00067757.PDFOctober 11, 2022
AlbertaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00058541.PDFOctober 30, 2020
AlbertaBiologics and BiosimilarsAdalimumabSIMLANDI™Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00068814.PDFDec 9, 2022
AlbertaBiologics and BiosimilarsAdalimumabYuflyma®Yes - S/AYes - S/ANAhttps://pdf.hres.ca/dpd_pm/00069429.PDFFebruary 3, 2023
British ColumbiaBiologics and BiosimilarsAdalimumabAbrilada®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHumira®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabSIMLANDIYes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabYuflyma®Yes - S/AYes - S/A
ManitobaBiologics and BiosimilarsAdalimumabAbrilada®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHumira®NoNo
ManitobaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabSIMLANDIYes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabYuflyma®Yes - EDSYes - EDS
New BrunswickBiologics and BiosimilarsAdalimumabAbrilada®NoNo
New BrunswickBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHumira®No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.
New BrunswickBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabSIMLANDINoNo
New BrunswickBiologics and BiosimilarsAdalimumabYuflyma®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAbrilada®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHumira®Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabSIMLANDIYes - S/AYes - SA
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabYuflyma®Yes - S/AYes - SA
NIHBBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHumira®Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.
NIHBBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHumira®Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U
Nova ScotiaBiologics and BiosimilarsAdalimumabAbrilada®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabHumira®No - barring exceptionNo - barring exception
Nova ScotiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabSIMLANDIYes - EDSYes - EDS
Nova ScotiaBiologics and BiosimilarsAdalimumabYuflyma®Yes - EDSYes - EDS
NunavutBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabHumira®Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.
NunavutBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/UNAhttps://pdf.hres.ca/dpd_pm/00068228.PDFNov 14, 2022
OntarioBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabHumira®Yes - L/UNo
OntarioBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
OntarioBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U
Prince Edward IslandBiologics and BiosimilarsAdalimumabAbrilada®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHadlima®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHumira®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabSIMLANDIYes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsAdalimumabYuflyma®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabAbrilada®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabHadlima®Yes - S/A Yes - S/A
QuebecBiologics and BiosimilarsAdalimumabHulio®Yes – S/A Yes – S/A
QuebecBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. If treatment and reimbursement began before March 3 2021.Yes - S/A. If treatment and reimbursement began before March 3 2021.
QuebecBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabSIMLANDIYes – S/AYes – S/A
QuebecBiologics and BiosimilarsAdalimumabYuflyma®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsAdalimumabAbrilada®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabHumira®NoNo
SaskatchewanBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDS
SaskatchewanBiologics and BiosimilarsAdalimumabSIMLANDIYes - EDSYes - EDS
SaskatchewanBiologics and BiosimilarsAdalimumabYuflyma®Yes - EDSYes - EDS
YukonBiologics and BiosimilarsAdalimumabAbrilada®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHumira®Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.Yes - L/U Effective june 11, 2021, all nihb program clients who are adalimumab-naïve and whose therapy is initiated on or after this date, an adalimumab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for humira before june 11, 2021 will continue to have this brand covered and will also be eligible for coverage of adalimumab biosimilars.
YukonBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabSIMLANDIYes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabYuflyma®Yes - L/UYes - L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00052133.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

AbbVie Care Support Program
https://abbviecare.ca/

Hadlima
Phone 1-866-556-5663 | https://harmonyorganon.ca/hadlima/en/index.html

Hyrimoz
Phone 1-888-6-SANDOZ (726369) | Email support.continum@sandoz.com

Idacio
Idacio KabiCare patient support program
https://kabicare.ca | Phone 1-888-304-2034| Email info@kabicare.ca

Amgevita
Enliven Services:
Phone: 1-877-936-2735 | Email amgevita@oneenliven.ca
www.amgevita.ca

Hulio
hulio.ca
Phone: 1-844-485-4677 | Email hulio@assistprogram.com

↑ Back to list of biologics and biosimilars

Infliximab (TNF Blocker)

How Does It Work?

Infliximab is a biologic that targets the overactive immune system in psoriasis. Infliximab works by supressing tumor necrosis factor-alpha (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Infliximab is an injectable medication that is administered intravenously, useful for psoriasis and psoriatic arthritis. Typically this is done in an infusion centre.

For plaque psoriasis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter

For psoriatic arthritis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.

What Are The Possible Side Effects?

The most common side effects of infliximab include temporary pain and redness around the infusion site, headaches, nausea, joint pain, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of infliximab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on infliximab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on infliximab.

Infliximab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Infliximab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with infliximab include cyclosporine, echinacea, phenytoin, and warfarin. For a complete list of medications that may interact with infliximab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/ANAhttps://pdf.hres.ca/dpd_pm/00065940.PDFMay 17, 2022
AlbertaBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00059824.PDF
AlbertaBiologics and BiosimilarsInfliximabRemicade®NoNo https://pdf.hres.ca/dpd_pm/00047753.PDFhttps://pdf.hres.ca/dpd_pm/00067676.PDFOct 07, 2022
AlbertaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00050544.PDFhttps://pdf.hres.ca/dpd_pm/00069528.PDFFeb 09, 2023
AlbertaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00047053.PDFhttps://pdf.hres.ca/dpd_pm/00057004.PDF
AlbertaBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
British ColumbiaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsInfliximabRemicade®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
British ColumbiaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsInfliximabRemsima®NoNo
British ColumbiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
ManitobaBiologics and BiosimilarsInfliximabAvsola®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsInfliximabInflectra®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabRemicade®Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.
ManitobaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabRemsima®NoNo
ManitobaBiologics and BiosimilarsInfliximabOmvyence™NoNo
New BrunswickBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabRemicade®No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.
New BrunswickBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabRemsima®NonNon
New BrunswickBiologics and BiosimilarsInfliximabOmvyence™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - SA
Newfoundland and LabradorBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; : Inflectra, Renflexis or Avsola are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). No
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemsima™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabOmvyence™NoNo
NIHBBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabRemicade®Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)
NIHBBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabRemsima™NoNo
NIHBBiologics and BiosimilarsInfliximabOmvyence™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemicade®Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)
Northwest TerritoriesBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabOmvyence™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemsima™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsInfliximabRemicade®No - barring exceptionNo - barring exception
Nova ScotiaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
Nova ScotiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabRemsima™NoNo
NunavutBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsInfliximabRemicade®Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)
NunavutBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsInfliximabRemsima™NoNo
NunavutBiologics and BiosimilarsInfliximabOmvyence™NoNo
OntarioBiologics and BiosimilarsInfliximabAvsola®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabRemicade®NoNo
OntarioBiologics and BiosimilarsInfliximabRenflexis®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsInfliximabOmvyence™NoNo
OntarioBiologics and BiosimilarsInfliximabRemsima™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabAvsola®NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabRemicade®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Prince Edward IslandBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRemsima™NoNo
QuebecBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
QuebecBiologics and BiosimilarsInfliximabInflectra®Yes - S/A Yes - S/A
QuebecBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. If treatment and reimburesement began before August 19, 2020 Yes – S/A. If treatment and reimburesment began before August 19, 2020 
QuebecBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
QuebecBiologics and BiosimilarsInfliximabOmvyence™NoNo
QuebecBiologics and BiosimilarsInfliximabRemsima™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabAvsola®Yes – EDS Yes – EDS
SaskatchewanBiologics and BiosimilarsInfliximabInflectra®Yes – EDS Yes – EDS
SaskatchewanBiologics and BiosimilarsInfliximabRemicade®NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRenflexis®Yes – EDS Yes – EDS
SaskatchewanBiologics and BiosimilarsInfliximabRemsima™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabOmvyence™NoNo
YukonBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabRemicade®Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)Yes - L/U (Effective may 1, 2017, all nihb program clients who are infliximab-naïve and whose therapy is initiated on or after this date, an infliximab biosimilar will be the product approved, provided the client meets the criteria for coverage and a biosimilar is indicated for the condition. Clients who received approval for remicade before may 1, 2017 will continue to have this brand covered and will also be eligible for coverage of infliximab biosimilars.)
YukonBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabRemsima™NoNo
YukonBiologics and BiosimilarsInfliximabOmvyence™NoNo

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Remicade®: https://pdf.hres.ca/dpd_pm/00047753.PDF
Inflectra®: https://pdf.hres.ca/dpd_pm/00047053.PDF
Renflexis®: https://pdf.hres.ca/dpd_pm/00050544.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Infliximab (Remicade®): https://www.bioadvancemember.ca/en/global/home
Infliximab biosimilar Inflectra®: https://www.pfizer.ca/assistance-programs
Infliximab biosimilar Renflexis®: http://www.merckharmony.ca/

Avsola
Enliven Services
Ph: 1-877-9ENBREL (936-2735) | Email info@oneenliven.ca
www.enbrel.ca; www.avsola.ca

Remsima
CELLTRION CONNECT™ patient support program for Remsima
Interested individuals can find out more about CELLTRION CONNECT™ by visiting www.celltrionconnect.ca/

↑ Back to list of biologics and biosimilars

Certolizumab pegol (TNF Blocker)

How Does It Work?

Certolizumab is a biologic that targets the overactive immune system in psoriasis. Certolizumab works by supressing tumor necrosis factor-alpha (TNFa).

Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Certolizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
400 mg every 2 weeks

For psoriatic arthritis:
400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks

What Are The Possible Side Effects?

The most common side effects of certolizumab include joint pain, and an increased risk of  upper respiratory tract infections and urinary tract infections. To obtain a comprehensive list of all known potential side effects of certolizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on certolizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on certolizumab.

Certolizumab should be avoided in patients with moderate to severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with certolizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with certolizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/Ahttps://pdf.hres.ca/dpd_pm/00049574.PDFhttps://pdf.hres.ca/dpd_pm/00053920.PDFNovember 13, 2019
British ColumbiaBiologics and BiosimilarsCertolizumab pegol Cimzia®N/AYes - S/A
ManitobaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
New BrunswickBiologics and BiosimilarsCertolizumab pegol Cimzia®Yes – S/A
Newfoundland and LabradorBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
NIHBBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes - L/U
Northwest TerritoriesBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes - L/U
Nova ScotiaBiologics and BiosimilarsCertolizumab pegol Cimzia®Yes - EDS Yes - EDS
NunavutBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes - L/U
OntarioBiologics and BiosimilarsCertolizumab pegol Cimzia®NoNo
Prince Edward IslandBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes
QuebecBiologics and BiosimilarsCertolizumab pegol Cimzia®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
YukonBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes - L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00049574.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

UCB Cares 1-800-908-5555

↑ Back to list of biologics and biosimilars

Golimumab (TNF Blocker)

How Does It Work?

Golimumab is a biologic that targets the overactive immune system in psoriatic arthritis. Golimumab works by supressing tumor necrosis factor-alpha (TNFa).

How Is It Used?

Golimumab is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of golimumab are an increased risk of infection and a temporary injection site reaction. To obtain a comprehensive list of all known potential side effects of golimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on golimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on golimumab.

Golimumab should be avoided in patients with severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with golimumab include abatacept, anakinra, baricitinib, belimumab, canakizumab, certolizumab pegol, cladribine, echinacea, infliximab, leflunomide, natalizumab, pimecrolimus, rilonacept, roflumilast, tacrolimus, tocilizumab, tofacitinib, and vedolizumab. For a complete list of medications that may interact with golimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00051840.PDFhttps://pdf.hres.ca/dpd_pm/00067454.PDFSeptember 9, 2022
British ColumbiaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
ManitobaBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
New BrunswickBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
NIHBBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
Northwest TerritoriesBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
Nova ScotiaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
NunavutBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
OntarioBiologics and BiosimilarsGolimumabSimponi®N/ANo
Prince Edward IslandBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
QuebecBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
SaskatchewanBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
YukonBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00051840.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://www.bioadvancemember.ca/en/global/home

↑ Back to list of biologics and biosimilars

Ixekizumab (IL17 Blocker)

How Does It Work?

Ixekizumab is a biologic that targets the overactive immune system in psoriasis. Ixekizumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ixekizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks

For psoriatic arthritis:
160 mg once, followed by 80 mg every 4 weeks

What Are The Possible Side Effects?

The most common side effects of ixekizumab include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ixekizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ixekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ixekizumab.

Ixekizumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ixekizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ixekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/A Yes – S/Ahttps://pdf.hres.ca/dpd_pm/00069828.PDF
British ColumbiaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/A Yes – S/A
ManitobaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
New BrunswickBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
NIHBBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Nova ScotiaBiologics and BiosimilarsIxekizumabTaltz®Yes - EDS Yes - EDS
NunavutBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
OntarioBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UNo
Prince Edward IslandBiologics and BiosimilarsIxekizumabTaltz®Yes - S/AYes – S/A
QuebecBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00047545.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Call 1-877-219-8908 for information.

↑ Back to list of biologics and biosimilars

Brodalumab (IL17 Blocker)

How Does It Work?

Brodalumab is a biologic that targets the overactive immune system in psoriasis. Brodalumab works by preventing interleukin-17 from causing inflammation.

How Is It Used?

Brodalumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks

What Are The Possible Side Effects?

The most common side effect of brodalumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of brodalumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on brodalumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on brodalumab.

Brodalumab should be avoided in patients with Crohn’s disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with brodalumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with brodalumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsBrodalumabSiliq™NoN/Ahttps://pdf.hres.ca/dpd_pm/00044076.PDFhttps://pdf.hres.ca/dpd_pm/00051682.PDFJune 7, 2019
British ColumbiaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
ManitobaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
New BrunswickBiologics and BiosimilarsBrodalumabSiliq™Yes – S/A
Newfoundland and LabradorBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
NIHBBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
Northwest TerritoriesBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
Nova ScotiaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
NunavutBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
OntarioBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
Prince Edward IslandBiologics and BiosimilarsBrodalumabSiliq™Yes - S/AN/A
QuebecBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
SaskatchewanBiologics and BiosimilarsBrodalumabSiliq™Yes – EDS N/A
YukonBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00044076.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Call 1-844-852-6967 for information.

↑ Back to list of biologics and biosimilars

Secukinumab (IL17 Blocker)

How Does It Work?

Secukinumab is a biologic that targets the overactive immune system in psoriasis. Secukinumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Secukinumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks

For psoriatic arthritis:
For patients not treated previously by a biological agent – 150 mg (or 300 mg for some patients) once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks. For those with previous treatment with a biologic agent – 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.

What Are The Possible Side Effects?

The most common side effect of secukinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of secukinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on secukinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on secukinumab.

Secukinumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with secukinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with secukinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
British ColumbiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
ManitobaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
New BrunswickBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
NIHBBiologics and BiosimilarsSecukinumabCosentyx®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsSecukinumabCosentyx®Yes - L/UYes - L/U
Nova ScotiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDS Yes - EDS
NunavutBiologics and BiosimilarsSecukinumabCosentyx®Yes - L/UYes - L/U
OntarioBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UNo 
Prince Edward IslandBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/A Yes – S/A
QuebecBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsSecukinumabCosentyx®Yes - L/UYes - L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00052362.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://www.cosentyx.ca/home/plaque-psoriasis/xpose-your-support-network/

↑ Back to list of biologics and biosimilars

Bimekizumab (IL17 Blocker)

How Does It Work?

Bimekizumab works by inhibiting the inflammatory proteins known as IL-17A and IL-17F. These inflammatory proteins are present in increased levels in psoriasis and by inhibiting them, this medication can help to achieve skin clearance and improvement in psoriasis symptoms.

How Is It Used?

Bimekizumab is an injectable medication that is administered subcutaneously. Patients can self-inject at home.

Bimekizumab is approved for the treatment of psoriasis. The recommended dose is 320mg (given as 2 subcutaneous injections of 160mg each) every 4 weeks for the first 16 weeks and then every 8 weeks thereafter.
If you weigh more than 120 kg, your healthcare professional may decide to continue your injections every 4 weeks from week 16. Follow your doctor’s instructions for optimal dosing.

Bimekizumab is available as a pre-filled syringe or autoinjector.

What Are The Possible Side Effects?

The most common side effects of bimekizumab include an increased risk of upper respiratory tract infection. To obtain a comprehensive list of all known potential side effects of bimekizumab, talk to your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on bimekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is safe to receive while on bimekizumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Bimekizumab is not recommended in patients with inflammatory bowel disease.

What Medications Interact With This Treatment?

For a complete list of medications that may interact with bimekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsBimekizumabBimzelx®Yes - S/AN/Ahttps://pdf.hres.ca/dpd_pm/00064702.PDFhttps://pdf.hres.ca/dpd_pm/00064702.PDFFebruary 14, 2022
British ColumbiaBiologics and BiosimilarsBimekizumabBimzelxYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00064702.PDF
ManitobaBiologics and BiosimilarsBimekizumabBimzelxYes - EDSN/A
New BrunswickBiologics and BiosimilarsBimekizumabBimzelxYes - S/ANo
Newfoundland and LabradorBiologics and BiosimilarsBimekizumabBimzelxNoN/A
NIHBBiologics and BiosimilarsBimekizumabBimzelxYes - L/UN/A
Northwest TerritoriesBiologics and BiosimilarsBimekizumabBimzelxYes - L/UN/A
Nova ScotiaBiologics and BiosimilarsBimekizumabBimzelxNos.o.
NunavutBiologics and BiosimilarsBimekizumabBimzelxYes - L/UN/A
OntarioBiologics and BiosimilarsBimekizumabBimzelx®Yes- L/UN/A
Prince Edward IslandBiologics and BiosimilarsBimekizumabBimzelx®Yes - S/AN/A
QuebecBiologics and BiosimilarsBimekizumabBimzelx®Yes - S/AN/A
SaskatchewanBiologics and BiosimilarsBimekizumabBimzelx®Yes – EDS N/A
YukonBiologics and BiosimilarsBimekizumabBimzelxYes - L/UN/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00064702.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

UCBCares Patient Support Program
1-800-908-5555
www.UCBCares.ca

↑ Back to list of biologics and biosimilars

Ustekinumab (IL12/23 Blocker)

How Does It Work?

Ustekinumab is a biologic that targets the overactive immune system in psoriasis. Ustekinumab works by suppressing interleukin 12 and interleukin 23. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ustekinumab is an injectable medication that is administered subcutaneously. Can be home dosed.

For plaque psoriasis:
≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter
>100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter

For psoriatic arthritis:
45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

What Are The Possible Side Effects?

The most common side effect of ustekinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ustekinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ustekinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ustekinumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ustekinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ustekinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsUstekinumabStelara®Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00048246.PDFhttps://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/stelara_cpm.pdfJanuary 5, 2023
British ColumbiaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
ManitobaBiologics and BiosimilarsUstekinumabStelara®Yes – EDS No
New BrunswickBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
NIHBBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Northwest TerritoriesBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Nova ScotiaBiologics and BiosimilarsUstekinumabStelara®Yes - EDS No
NunavutBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
OntarioBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Prince Edward IslandBiologics and BiosimilarsUstekinumabStelara®Yes-S/ANo
QuebecBiologics and BiosimilarsUstekinumabStelara®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsUstekinumabStelara®Yes – EDSYes – EDS
YukonBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00048246.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://www.bioadvancemember.ca/en/global/home

↑ Back to list of biologics and biosimilars

Risankizumab (IL23 Blocker)

How Does It Work?

Risankizumab is a biologic that targets the overactive immune system in psoriasis. Risankizumab works by supressing interleukin-23A.

How Is It Used?

The recommended dose of SKYRIZI is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. 

What Are The Possible Side Effects?

The most common side effect of risankizumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of risankizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on risankizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on risankizumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

N/A

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsRisankizumabSkyrizi®Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00069300.PDF
British ColumbiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
ManitobaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
New BrunswickBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
Newfoundland and LabradorBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
NIHBBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Northwest TerritoriesBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Nova ScotiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDS N/A
NunavutBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
OntarioBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Prince Edward IslandBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
QuebecBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
SaskatchewanBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
YukonBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00050697.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://abbviecare.ca/

↑ Back to list of biologics and biosimilars

Guselkumab (IL23 Blocker)

How Does It Work?

Guselkumab is a biologic that targets the overactive immune system in psoriasis. Guselkumab works by neutralizing interleukin-23.

How Is It Used?

Guselkumab is an injectable medication that is administered subcutaneously by injection. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.

For plaque psoriasis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

For psoriatic arthritis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

The most common side effect of guselkumab is an increased risk of respiratory tract infections. To obtain a comprehensive list of all known potential side effects of guselkumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on guselkumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on guselkumab.

Patients should be screened for tuberculosis and infections prior to treatment.

Do not use TREMFYA®/TREMFYA One-Press™ if you are allergic to guselkumab or any of the ingredients in TREMFYA®/TREMFYA OnePress™.

If you think you are allergic, ask your healthcare professional for advice before using TREMFYA®/TREMFYA One-Press™.

 

What Medications Interact With This Treatment?

For a complete list of medications that may interact with guselkumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

 

 

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsGuselkumabTremfya®NoNohttps://pdf.hres.ca/dpd_pm/00057930.PDFhttps://pdf.hres.ca/dpd_pm/00068091.PDFNovember 8, 2022
British ColumbiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
ManitobaBiologics and BiosimilarsGuselkumabTremfya®NoNo
New BrunswickBiologics and BiosimilarsGuselkumabTremfya®NoNo
Newfoundland and LabradorBiologics and BiosimilarsGuselkumabTremfya®NoNo
NIHBBiologics and BiosimilarsGuselkumabTremfya®NoNo
Northwest TerritoriesBiologics and BiosimilarsGuselkumabTremfya®NoNo
Nova ScotiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
NunavutBiologics and BiosimilarsGuselkumabTremfya®NoNo
OntarioBiologics and BiosimilarsGuselkumabTremfya®NoNo
Prince Edward IslandBiologics and BiosimilarsGuselkumabTremfya®NoNo
QuebecBiologics and BiosimilarsGuselkumabTremfya®NoNo
SaskatchewanBiologics and BiosimilarsGuselkumabTremfya®NoNo
YukonBiologics and BiosimilarsGuselkumabTremfya®NoNo

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Health Canada Product Monograph
https://pdf.hres.ca/dpd_pm/00057930.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://www.bioadvancemember.ca/en/global/home

↑ Back to list of biologics and biosimilars

Abatacept

How Does It Work?

Abatacept is a biologic that targets the overactive immune system in psoriatic arthritis. Abatacept works by supressing the activation of white blood cells called T-cells.

How Is It Used?

Abatacept is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of abatacept are headache, nausea, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of abatacept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on abatacept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on abatacept.

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of experience COPD-related adverse events such as cough, shortness of breath, and infection while on abatacept.

Abatacept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with abatacept include anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, baricitinib, belimumab, cladribine, echinacea, leflunomide, natalizumab, pimecrolimus, rituximab, roflumilast, tacrolimus, tocilizumab, and tofacitinib. For a complete list of medications that may interact with abatacept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsAbataceptOrencia®N/ANohttps://pdf.hres.ca/dpd_pm/00045017.PDFhttps://pdf.hres.ca/dpd_pm/00066773.PDFJuly 21, 2022
British ColumbiaBiologics and BiosimilarsAbataceptOrencia®N/ANo
ManitobaBiologics and BiosimilarsAbataceptOrencia®N/ANo
New BrunswickBiologics and BiosimilarsAbataceptOrencia®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAbataceptOrencia®N/ANo
NIHBBiologics and BiosimilarsAbataceptOrencia®N/ANo
Northwest TerritoriesBiologics and BiosimilarsAbataceptOrencia®N/ANo
Nova ScotiaBiologics and BiosimilarsAbataceptOrencia®N/ANo
NunavutBiologics and BiosimilarsAbataceptOrencia®N/ANo
OntarioBiologics and BiosimilarsAbataceptOrencia®N/ANo
Prince Edward IslandBiologics and BiosimilarsAbataceptOrencia®N/AYes - S/A
QuebecBiologics and BiosimilarsAbataceptOrencia®N/AYes - S/A
SaskatchewanBiologics and BiosimilarsAbataceptOrencia®N/ANo
YukonBiologics and BiosimilarsAbataceptOrencia®N/ANo

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00045017.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

↑ Back to list of biologics and biosimilars

Tildrakizumab

How Does It Work?

Ilumya™ acts on specific molecular signals used by the immune system to decrease the immune system’s overactivity that can contribute to plaque psoriasis.

How Is It Used?

Ilumya™ is a drug taken by injection often in 12-week intervals.

What Are The Possible Side Effects?

Side effects of Ilumya™ can include diarrhea, skin irritation and muscle pain at the injection site, fatigue, increased risk of infection, joint pain, and headaches. To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.

Any Other Important Considerations?

Not applicable

What Medications Interact With This Treatment?

Certain vaccines cannot be taken while on Ilumya™. Talk to your doctor before being vaccinated to confirm it is safe to do so while on Ilumya. Ilumya may also interact with dextromethorphan. Ask your doctor or pharmacist if you are concerned about a drug interaction.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:
AlbertaBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/Ahttps://pdf.hres.ca/dpd_pm/00060995.PDFhttps://pdf.hres.ca/dpd_pm/00064464.PDFJanuary 24, 2022
British ColumbiaBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
ManitobaBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDS N/A
New BrunswickBiologics and BiosimilarsTildrakizumabIlumya™Yes - S/AN/A
Newfoundland and LabradorBiologics and BiosimilarsTildrakizumabIlumya™Yes – S/AN/A
NIHBBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
Northwest TerritoriesBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
Nova ScotiaBiologics and BiosimilarsTildrakizumabIlumya™Yes – EDSN/A
NunavutBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A
OntarioBiologics and BiosimilarsTildrakizumabIlumya™Yes – L/UN/A
Prince Edward IslandBiologics and BiosimilarsTildrakizumabIlumya™Yes-S/AN/A
QuebecBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
SaskatchewanBiologics and BiosimilarsTildrakizumabIlumya™Yes – EDSN/A
YukonBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00060995.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

↑ Back to list of biologics and biosimilars

SPEVIGO® (IL 36 Blocker)

How Does It Work?

SPEVIGO (spesolimab for injection) inhibits the inflammatory signaling pathway of interleukin 36 (IL-36), and is indicated for the treatment of flares in adult patients with generalized pustular psoriasis (GPP).

How Is It Used?

Treatment with SPEVIGO (spesolimab for injection) should be initiated by physicians experienced in the management of patients with inflammatory skin diseases.

The recommended dose of SPEVIGO (spesolimab for injection) is a single dose of 900 mg (2 x 450 mg/7.5 ml vials) administered as an intravenous infusion. If flare symptoms persist, an additional 900 mg dose may be administered 1 week after the initial dose.

What Are The Possible Side Effects?

The most common side effects of SPEVIGO (spesolimab for injection) include fatigue/weakness, nausea and vomiting, headache, itching or itchy bumps, a collection of blood under the skin at the infusion site or bruising, and urinary tract infection. To obtain a comprehensive list of all known potential side effects of roflumilast, talk to your doctor or pharmacist.

Any Other Important Considerations?

SPEVIGO (spesolimab for injection) is contraindicated in patients with severe or life-threatening hypersensitivity to this drug or to any ingredients in the formulation, including any non-medicinal ingredients, or components of the container.

What Medications Interact With This Treatment?

No formal drug-drug interaction studies were conducted with SPEVIGO (spesolimab for injection). For a complete list of medications that may interact with SPEVIGO (spesolimab for injection) and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisCurrent MonographUpdated MonographDate of Revision:

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102523

https://pdf.hres.ca/dpd_pm/00070263.PDF

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

headstartGO@supportprogram.com

Call toll-free: 1-833-773-4746

MedInfo can be accessed by health care providers for possible inquiries (1-800-263-5103 x84643, zrburmedinfo@boehringer-ingelheim.com).

↑ Back to list of biologics and biosimilars

Last updated October, 2022